Mechanism #
Serotonin reuptake inhibition and 5-HT1A partial agonism.
Clinical distinction #
Food and labelled titration affect exposure and tolerability.
Monitoring and warnings #
Gastrointestinal effects, serotonin syndrome and discontinuation symptoms; review CYP3A4 modifiers.
Formulation scope #
Oral tablet.
Dose reference #
| Indication | Population | Formulation / route | Jurisdiction | Reference |
|---|---|---|---|---|
| MDD | Adults; general label population only. See separate impairment/age restrictions. | oral tablet · oral | United States | Adult labelled titration: 10 mg/day with food for seven days, then 20 mg/day with food. Target 20–40 mg/day; at least seven days between subsequent increases. |
Special populations & counseling #
Age, renal and hepatic function, pregnancy, breastfeeding, co-medication and the treatment indication require medicine-specific review. A general class statement cannot establish suitability for an individual.
Discuss the intended benefit, expected review plan, relevant adverse effects, driving or falls considerations, and how to obtain help. Stopping, switching or restarting requires the exact product’s instructions and clinical assessment.
Brands & products #
Supplied catalogue observations; price dates may be unknown. Presence does not establish current stock or Indian approval.
Reference coverage #
Ingredient profiles and product records are separate. Details not supplied in this reference must be checked in the exact product information; missing information is not evidence of absence or safety.
References · 3
- DailyMed structured product information · Retrieved 2026-10-07
- MHRA product information · Retrieved 2026-10-07
- CDSCO approved new drugs · Retrieved 2026-10-07